Sixth Street Specialty Lending (TSLX) : 11-year performance

  

 

Ocugen (OCGN) : 10-year performance

Sector: Healthcare

Industry: Biotechnology

Founded: 2013

Headquarters: Malvern, Pennsylvania

Website: https://www.ocugen.com

Employees: 95

IPO: December 3, 2014

Ticker: OCGN

September 30, 2019: Ocugen (OCGN) completed a reverse merger with Histogenics (Nasdaq: HSGX), creating a company focused on developing therapies for ocular diseases, operating under the Ocugen name.

Pulmatrix, Inc. (PULM) : 10-year performance

Pulmatrix, Inc., a clinical stage biotechnology company, focused on development of novel inhaled therapeutic products to prevent and treat respiratory and other diseases with unmet medical needs in the United States.

• Sector: Healthcare
• Industry: Biotechnology
• Full Time Employees: 22
• Founded by David Alan Edwards, Mark J. Gabrielson, Alexander M. Klibanov, and Robert S. Langer, Jr. in April 2003 
• Headquartered in Framingham, Massachusetts
• http://www.pulmatrix.com

IPO: March 7, 2014

Nov 13, 2024: Pulmatrix, Inc. (NASDAQ:PULM) announced a definitive merger agreement with Cullgen Inc.

U.S.-listed IPOs, annual deal count and value

The value of new U.S. stock listings has only ticked up modestly from 2022, when rapidly rising interest rates and COVID-related distortions in some industries depressed IPO activity.

As of December 31, 2024. Source: Bloomberg Finance L.P.

Wins Finance (WINS) delisted from Nasdaq

• Sector(s): Financial Services
• Industry: Asset Management
• Full Time Employees: 24
• HQ: Beijing, China
• http://www.winsholdings.com 

The origins of Wins Finance as a publicly listed company start with Sino Mercury Acquisition Corporation (SMAC), which was formed as a special-purpose acquisition company. SMAC had been established and listed on the Nasdaq in 2014. The intention of forming the shell company was to raise money and serve as a backdoor for a Chinese company in the non-traditional financial sector to become listed in the US. The founders of SMAC were Richard Xu and Brad Reifler. The sole book runner on the IPO was Cantor Fitzgerald.  SMAC's August 2014 IPO on the Nasdaq would raise $40 million.

Wins Finance was the target Chinese company acquired by SMAC in 2015 with the merged entity taking the name of Wins Finance. It would start trading on the Nasdaq in October 2015.

Pfizer (PFE) and GlycoMimetics (GLYC) reports Top-Line Phase 3 results for Rivipansel; study did not meet its primary or key secondary endpoints

** charts after announcement **

 

Co announced today that the Phase 3 Rivipansel (GMI-1070): Evaluating Safety, Efficacy and Time to Discharge (RESET) pivotal study did not meet its primary or key secondary efficacy endpoints. 

The objective of the trial was to evaluate the efficacy and safety of rivipansel in patients aged six and older with sickle cell disease (SCD) who were hospitalized for a vaso-occlusive crisis (VOC) and required treatment with intravenous (IV) opioids. The primary endpoint was time to readiness-for-discharge and the key secondary efficacy endpoints were time-to-discharge, cumulative IV opioid consumption, and time to discontinuation of IV opioids.

Detailed analyses of the RESET study, including additional data on efficacy and safety endpoints, which are not available at this time, will be submitted for presentation at a future scientific meeting.

Detailed analyses of the RESET study, including additional data on efficacy and safety endpoints, which are not available at this time, will be submitted for presentation at a future scientific meeting.

** charts before  announcement **

 

Papa Murphy's to be acquired by MTY Food Group for $6.45/share

• 2014 IPO

 

MTY Food Group

Papa Murphy's to be acquired by Canadian company MTY Food Group for $6.45/share in cash, or approximately $190 mln

Papa Murphy's is a franchisor and operator of the largest Take ‘n’ Bake pizza brand and the 5th largest pizza chain in the United States, selling fresh, hand-crafted pizzas ready for customers to bake at home. In addition to scratch-made pizzas, Papa Murphy’s offers a growing menu of grab 'n' go items, including salads, sides and desserts. Papa Murphy’s was founded in 1981 and operated 1,331 franchised and 106 corporate-owned stores in 37 U.S. states, Canada and the United Arab Emirates as of December 31, 2018.

** charts before announcement **

 

Paycom Software (PAYC) reported earnings on Tue 5 Feb 2019 (a/h)

 Paycom Software, Inc. , known simply as Paycom, provides cloud-based human capital management (HCM) software service for small to mid-sized companies in the United States. It provides functionality and data analytics that businesses need to manage the employment life cycle from recruitment to retirement.

• Sector: Technology
• Industry: Software - Application
• Full Time Employees: 2,548
• Founded in 1998 
• Headquartered in Oklahoma City, Oklahoma
• http://www.paycom.com

 

Paycom Software beats by $0.05, beats on revs; guides Q1 revs above consensus; guides FY19 revs above consensus

• Reports Q4 (Dec) earnings of $0.61 per share, excluding non-recurring items, $0.05 better than the S&P Capital IQ Consensus of $0.56; revenues rose 31.8% year/year to $150.33 mln vs the $144.1 mln S&P Capital IQ Consensus.
• Adjusted EBITDA was $57.5 million, compared to $48.4 million in the same period last year, as adjusted.
• Co issues upside guidance for Q1, sees Q1 revs of $194-196 mln vs. $190.95 mln S&P Capital IQ Consensus; sees Adjusted EBITDA in the range of $97.0 million to $99.0 million.
• Co issues upside guidance for FY19, sees FY19 revs of $710-712 mln vs. $696.66 mln S&P Capital IQ Consensus; sees Adjusted EBITDA in the range of $288.0 million to $290.0 million.

TerraForm Power (TERP) : 3-year performance

Sector: Utilities > Industry: Renewable Utilities

• Headquarters: Bethesda, Maryland
• Founded: 2014
• terraformpower.com

• Brookfield Renewable Partners L.P. (BEP) announced that, together with its institutional partners, it has closed the previously-announced acquisition of a 51% interest in TerraForm Power (TERP), a large scale, diversified portfolio of solar and wind assets located predominantly in the U.S., for a total commitment of $656 million.

  

** monthly **

************

Description

TerraForm Power, Inc. is a United States-based holding company. The Company owns clean power generation assets. This includes solar and wind assets located in the United States, Canada and other markets. Its clean power generation assets serve utility, commercial and residential customers. As of December 31, 2016, the Company's portfolio consisted of renewable energy facilities located in the United States, Canada, the United Kingdom and Chile with a combined nameplate capacity of 2,983.1 megawatts. It owns and operates over 500 hundred wind and solar clean energy power installations. Its projects include Bluebird, River Mountains Solar, Laho Solar, SunE Perpetual Lindsday, Sandringham, California Public institutions and Summit Solar Projects. The Company holds interest in TerraForm Power, LLC (Terra LLC), which is an owner and operator of renewable energy facilities that have long-term contractual arrangements to sell the electricity generated by these facilities to third parties.

Key stats and ratios

	Q2 (Jun '17)	2016
Net profit margin	-0.40%	-36.90%
Operating margin	15.00%	13.43%
EBITD margin	-	63.55%
Return on average assets	-0.04%	-3.03%
Return on average equity	1.68%	-10.98%

Corbus Pharma (CRBP) : mid-stage results for inflammatory disease drug

• The drug, anabasum, is intended for the rare inflammatory condition dermatomyositis, which is associated with an itchy and painful rash and progressive muscle weakness, according to the Mayo Clinic. 

Ticker: CRBP

Corbus Pharma announces 'positive' topline results from its Phase 2 study of anabasum in dermatomyositis

• The mean improvement (reduction) in the primary efficacy outcome, the Cutaneous Dermatomyositis Disease Area and Severity Index ("CDASI") activity score, a validated outcome measure of skin disease severity, was 9.3 points for anabasum treatment at the end of the study versus a reduction of 3.7 points for placebo treatment.
• Anabasum also outperformed placebo in multiple secondary efficacy outcomes studied.

***

In the clinical trial, which enrolled 22 adults and lasted 16 weeks, the drug outperformed the placebo in the primary efficacy outcome and in multiple secondary efficacy outcomes, the company said. There were also no signs of safety issues, Corbus said. Currently, "we have little to offer patients with moderate to severe disease activity except immunosuppressive therapies with often limited efficacy and significant side effects," said Dr. Victoria Werth, a principal investigator in the study and a professor of dermatology at the Hospital of the University of Pennsylvania. Corbus Pharma shares have surged 6.9% over the last three months to $7.00 per share.

** charts day before  announcement **